CURRICULUM VITAE

RAVI RAVINUTHALA, MD, MRCP, FAASLD

CURRRENT POSITIONS:

Gastroenterologist and Transplant Hepatologist
Ohio GI and Liver Institute, Cincinnati, OH

Medical Director, Ohio GI Liver Clinic
Ohio GI and Liver Institute

Medical Director, Mercy Health Liver & Pancreas Center
Jewish Hospital, Cincinnati

Associate Professor of Medicine
Division of Gastroenterology, University of Kentucky

Vol. Associate Professor of Medicine
Division of Digestive Diseases, University of Cincinnati

DESCRIPTION OF CURRENT POSITIONS:

Medical Director, Ohio GI Liver Clinic:

Ohio Gastroenterology & Liver Institute is the largest single specialty Gastroenterology Private Practice group in the Tri-State area. It was established 65 years ago and has 21 gastroenterologists. Liver Clinic is a dedicated facility in Blue Ash with on site dedicated ultrasound services, Liver Clinical Research staff, paracentesis facility. There is close coordination with outpatient surgery centers where we do liver biopsies, diagnostic and therapeutic paracentesis, esophageal pill cams, variceal band ligation, in addition to regular endoscopies.

I also manage three special programs within the liver clinic.

- NASH program is dedicated to manage people with non alcoholic fatty liver disease. Patients are treated according to evidence based protocols incorporating cutting edge treatments and holistic management. We have excellent results and are in the process of publishing our large volume of data. We collaborate with Cincinnati Children's Hospital NASH Clinic (part of NIH CRN network) and children from their NASH clinic transition to our adult clinic as they grow older.
- Viral Hepatitis program involves treatment of Hepatitis C and Hepatitis B patients with latest treatments according to evidence based protocols. We have dedicated staff well experienced in managing adverse effects and providing support to patients on treatment. The on-site liver research facility actively enrolls in cutting edge clinical trials. I am also actively involved in teaching healthcare providers locally and nationally.

- Cirrhosis program is designed to care for our patients with advanced liver disease. The management is protocol based with aim to prolong survival and manage complications. We also provide support for the patients and their families realizing that chronic liver disease affects families deeply. Hepatocellular cancer screening is accomplished with on site ultrasound exams and an on-site phlebotomist makes it convenient for lab draws.

Medical Director, Mercy Health Liver Center:

I partnered with Mercy Health System in developing a comprehensive Liver Center to specifically care for patients with End stage Liver Disease. Mercy Health System is one of the largest health systems in the area with 19 hospitals. The Liver Center is based at the Jewish Hospital and has a dedicated floor with trained staff and evidence based protocols in place. We measure outcomes meticulously and plan to publish the data soon.

For patients who need liver transplantation, I have partnered with University of Kentucky and University of Cincinnati. Patients are evaluated in the UK Northern Kentucky Clinic or University of Cincinnati Medical center and if necessary, are transferred from Jewish Hospital to Lexington. Some patients are also transferred to University of Cincinnati.

Given the different organ allocation pools of University of Kentucky and University of Cincinnati, our liver clinic patients get dual listed at both centers (serving two different regions) to increase patients' chance of getting an organ.

PROFESSIONAL EDUCATION & EXPERIENCE:

1983 – 1990 Rangaraya Medical College Kakinada, India
Medical School

1991 – 1994 PGIMER Chandigarh, India
Internal Medicine Residency & Senior Residency
- One of the two apex central Institutions for advanced training in India
- Graduated first in class

1995 – 1996 University Hospital of Wales Cardiff, UK
Registrar & Senior House Officer in Gastroenterology & Internal Medicine
- Experience in a prominent Inflammatory Bowel Disease unit
- Largest medical school in Western Europe

CURRICULUM
VITAE

RAVI RAVINUTHALA, MD, MRCP, FAASLD

1996 – 1997 St. James University Hospital Leeds, UK
Senior House Officer in Medical Transplant Hepatology
- 150 liver transplants–a-year center with dedicated liver unit
- Extensive training in Acute Liver Failure ICU management
- Largest hospital in Western Europe

1997 – 2000 Henry Ford Hospital Detroit, MI
Internal Medicine Resident

2000 – 2003 Henry Ford Hospital Detroit, MI
Gastroenterology & Hepatology Fellow

2003 – 2004 **Senior Staff Physician (Faculty)**
Hepatology & Gastroenterology
Henry Ford Hospital, Detroit, MI

2004 – present Ohio GI and Liver Institute (formerly
Greater Cincinnati Gastroenterology Associates)
Private Practice in Gastroenterology and Hepatology
2925 Vernon Place, Suite 100 & 8271 Cornell Road
Cincinnati, Ohio 45219 Cincinnati, Ohio 45249
(513) 751-6667

2004 – present Consultants for Clinical Research, Inc
Primary & Sub investigator in Gastroenterology and Hepatology Research
2925 Vernon Place, Suite 200
Cincinnati, Ohio 45219
(513) 872-4549

BOARD CERTIFICATIONS:

Gastroenterology
Transplant Hepatology

PROFESSIONAL MEMBERSHIPS:

American Association for the Study of Liver Diseases (AASLD)
Royal College of Physicians of United Kingdom (MRCP)

CURRICULUM VITAE

RAVI RAVINUTHALA, MD, MRCP, FAASLD

LICENSURE:

Ohio License 35-084651
General Medical Council of United Kingdom license

STAFF APPOINTMENTS:

Mercy Jewish Hospital - Kenwood
Bethesda North Hospital
Christ Hospital

HONORARY APPOINTMENTS:

Medical Advisor, Asian Indian Alliance
Board Member, Jewish Hospital Medical Executive Committee
Member, Quality Committee , Mercy Health Select ACO
Member, Medical Advisory Board, LifeCenter

PUBLICATIONS:

Rosiglitazone Toxicity
Ravi Ravinuthala & Uday Nori
Annals of Internal Medicine 2000; 133:658

The Effects of Oral Pancreatic Enzymes (Creon 10 Capsule) on Steatorrhea. A Multicenter, Placebo-controlled, Parallel Group Trial in Subjects With Chronic Pancreatitis.
Michael Safdi, MD, * Pradeep K. Bekal, MD, * Stephen Martin, MD, * Zahid A. Saeed, MD, * Frank Burton, MD, † and Phillip P. Toskes, MD‡

A Multicenter, Randomized, Phase 2a Study of Human Monoclonal Antibody to IL-12/23p40 (CNTO 1275) in Patients With Moderately to Severely Active Crohn's Disease. William Sandborn, Brian Feagan, Richard Fedorak, Ellen Scherl, Mark Fleisher, Seymour Katz Jewel Johanns, Marion Blank, Paul Rutgeerts.

The Effect of Human Monoclonal Antibody to IL-12/23p40 (CNTO 1275) on Serum Levels of Inflammation-related Proteins in Patients with Moderately to Severely Active Crohn's Disease. Willem deVilliers, Gary Toedter, Grace Liu, Marion Blank, Scott Plevey

Adult onset urea cycle disorder in a patient with presumed hepatic encephalopathy.
Atiq M, Holt AF, Safdar K, Weber F, Ravinuthala R, Jonas ME, Neff GW.
J Clin Gastroenterol. 2008 Feb;42(2):213-4.

CURRICULUM
VITAE

RAVI RAVINUTHALA, MD, MRCP, FAASLD

PUBLICATIONS:

Prevalence of hepatitis A virus antibodies in patients with cirrhosis
Ravinuthala, Ravi V. | Brown, Kimberly A. | Moonka, Dilip
The American Journal of Gastroenterology, ISSN: 00029270, Vol: 97, Issue: 9,
Date: September, 2002, Pages: S89-S89

Complete ablation of bleeding stromal tumor of stomach with left gastric artery embolization
Ravinuthala, Ravi V. | Ben-Menachem, Tamir
The American Journal of Gastroenterology, ISSN: 00029270, Vol: 97, Issue: 9,
Date: September, 2002, Pages: S156-S156

Transjugular Intrahepatic Portosystemic Shunts for Refractory Ascites after Liver Transplantation. Transplant Proceedings 2005, in press.
M. Abouljoud, A. Yoshida, D. Kim, J. Jerius, D. Moonka, R. Ravinuthala, K. Brown.

Transjugular Intrahepatic Portosystemic Shunts for Refractory Ascites after Liver Transplantation. Transplantation: 27 July 2004 - Volume 78 - Issue 2 - p 386

Safety, tolerability and efficacy of interferon alfa 2b and Ribavirin combination therapy in HCV patients with cirrhosis Ravi Ravinuthala, Vosudesh Pai, Dilip Moonka, Kimberly Brown Gastroenterology Volume 124, Issue 4, Supplement 1 , Page A383, April 2003

Clostridium difficile Infection Was Not Detected in Patients
Who Received Rifaximin for Hepatic Encephalopathy in Community
and University Practices. ACG 2008 Poster Guy Neff, MD, V. Zacharias, MD, M. Jones, MD, M. Jonas, MD, R. Ravinuthala, MD, D. Novick, MD, T. Kaiser, MD, N. Kemmer, MD, University of Cincinnati College of Medicine, Cincinnati, OH, TriState Gastroenterology Associates, Dayton, OH, Greater Cincinnati Gastroenterology Associates, Cincinnati, OH, Digestive Specialists, Inc, Dayton, OH

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J Sandborn, M.D., Christopher Gasink, M.D., Long-Long Gao, Ph. D., Marion A. Blank, Ph. D., Jewel Johanns, Ph. D., Cynthia Guzzo, M.D., Bruce E. Sands, M.D., Stephen B Hanuaer, M.D., Stephan Targan NM.D., Paul Rutgeerts, M.D., Ph. D., Subrata Ghosh, M.D., Willem J. S. deVilliers, M.D., Ph. D., Remo Panaccione, M.D., Gordon Greenberg, M.D., Stefan Schreiber, M.D., Simon Lichtiger, M.D., and Brian G. Feagan M.D. for the CERTIFI Study Group* The New England Journal of Medicine 2012, VOL. 367 NO. 16, October 18, 2012.

* Dr. Ravinuthala is a member of this study groups.

RAVI RAVINUTHALA, MD, MRCP, FAASLD

CLINICAL RESEARCH

Hepatology Trials:

"Phase 2B, Partially Blinded, Randomized Study In Treatment Naïve Subjects With HCV Genotype 1 To Compare The Efficacy, Safety, And Tolerability Of Three Doses of LoctEron™ Plus Ribavirin Given Bi-weekly In Comparison WiTh PEG-Intron™ Plus Ribavirin Given Weekly" BLX883-203 (SELECT-2)

A Phase 2b, Randomized, Double-Blind, Placebo Controlled Trial Evaluating 16 and 24 Weeks of a Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir
(GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection (Protocol GS-US-196-0140)

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic Hepatitis C Virus (HCV) Infection (GS-US-196-0103)

A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of the Safety and Anti-Fibrotic Efficacy of Interferon-gamma 1b (IFN-γ 1b) in Patients with Severe Liver Fibrosis or Compensated Cirrhosis Due to Hepatitis C. GILF-001

Multicenter, randomized, open-label, controlled study of the effect of treatment with once weekly Pegasys® plus daily Copegus® with or without concomitant pioglitazone (Actos®) on early viral kinetics in treatment-naïve patients with chronic hepatitis C (genotype 1 HCV infection) and insulin resistance (ML21301)

Prospective observational study on predictors of early on-treatment response and sustained virological response in a cohort of treatment naïve HCV-infected patients treated with pegylated interferons (Prophesys 3)

A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2a and ribavirin in treatment-naïve, genotype 1 hepatitis C-infected subjects. (TMC435-TiDP16-C208)

RAVI RAVINUTHALA, MD, MRCP, FAASLD

Hepatology Trials:

A Phase III, open-label trial of TMC435 in combination with peginterferon alpha-2a and ribavirin for HCV genotype-1 infected subjects who participated in the placebo group of Phase II/III TMC435 study (C201, C205, C206, C208, C216 and HPC3007), or who received short- term (up to 14 days) direct-acting antiviral treatment for hepatitis C infection in a selected Tibotec-sponsored Phase I study. (TMC435-TiDP16-C213)

Comparison of Weight-based Doses of Taribavirin Combined with Peginterferon Alfa-2b Versus Ribavirin Combined with Peginterferon Alfa-2b in Therapy-naïve Patients With Chronic Hepatitis C Virus Genotype 1 Infection (Protocol RNA003142-204)

A Randomized, Parallel Group, Dose-Ranging Study to Evaluate Efficacy , Safety, Pharmacokinetics, and Antiviral Activity of VX 222 and Telaprevir in Combination With and Without Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C (VX09-222-103)

A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genotype 1 chronic hepatitis C virus infection (VX-950-C211)

A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C who Achieve an Extended Rapid Viral Response (eRVR) While Receiving Telaprevir, Peginterferon Alfa2a (Pegasys®) and Ribavirin (Copegus®) (VX08-950-111)

A Phase 2, Randomized, Open-Label Study Of The Safety, Antiviral Activity, And Pharmacokinetics Of Hcv-796 Administered In Combination With Peginterferon Alfa 2b (Peg- Intron) Plus Ribavirin (Rebetol) Versus Peg-Intron Plus Rebetol In Subjects With Hepatitis C Virus Genotype 1 Infection (Protocol Number: 3173a1-200-US)

An Open-Label Trial of Pegylated Interferon plus Ribavirin in Combination with CTS-1027 in HCV Null-Responders (Protocol CTS-1027-04)

A Dose Response Study of CTS-1027 in Hepatitis C Patients (CTS-1027-01)

A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders (CTS-1027-05)

A Trial of CTS-1027 in Interferon-Naïve Hepatitis C Patients (Protocol CTS-1027-03)

A Prospective 3-year Follow-up Study in Subjects Previously Treated in a Phase IIb or Phase III Study with A TMC435-Containing Regimen for the Treatment of Hepatitis C Virus (HCV) Infection. (TMC435-HPC-3002)

CURRICULUM
VITAE

RAVI RAVINUTHALA, MD, MRCP, FAASLD

Hepatology Trials:

A Phase III, Randomized, Double-Blind Trial to Evaluate the Efficacy, Safety and Tolerability of TMC435 vs. Telaprevir, Both in Combination with PegIFN-2a and Ribavirin, in Chronic Hepatitis C genotype-1 Infected Subjects Who Were Null or Partial Responders to Prior PegIFNa and Ribavirin Therapy (TMC435HPC3001)

A Phase II double-blind, placebo-controlled study of two doses of EPA-E in patients with NASH through Mochida Pharmaceutical CO., LTD (Protocol MCH-02-001)

A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1a Chronic Hepatitis C Virus (HCV) Infection (PEARL-IV)

An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (pegIFN/RBV) in Chronic Hepatitis C Virus (HCV) Infected Subjects Who Have Experienced Virologic Failure in a Previous Abbvie or Abbott DAA Combination Study. M13-101

A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, with and without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combination with Ribavirin, in the Treatment of Naïve Genotype 2 and 3 Chronic Hepatitis C Subjects. AI452-017

A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which BMS-914143 was Administered for the Treatment of Chronic Hepatitis C AI452-016
A Prospective Observational Study to Examine Patient Characteristics, Health Care Management, and Effectiveness Among HVC Patients Treated with Simeprevir at Various Practice Settings (Sonet) TMC435HPC4003

Collection of Blood Samples from Subjects Infected with Chronic Hepatitis C (Genotypes 2 and 3) and Treated with Sofosbuvir plus Ribavirin (COL-HCV-343)

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications in Subjects with Early Decompensated Liver Cirrhosis (RNLC2131)
CENTAUR Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis (652-2-203)

RAVI RAVINUTHALA, MD, MRCP, FAASLD

Gastroenterology Trials:

A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderately to Severely Active Ulcerative Colitis. (M06-827)

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Renzapride in Women with Constipation-Predominant Irritable Bowel Syndrome (c-IBS) Protocol: ATL1251/038/CL

A Phase III, Multicenter, Open Label, Extension Study to Evaluate the Long-term Safety of Renzapride 4 mg Once Daily in Women with Constipation-Predominant Irritable Bowel Syndrome (c-IBS) Protocol: ATL1251/052/CL

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in subjects with Moderately to Severly Active Crohn's Disease Wo Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1) - CNTO1275CRD3001

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severly Active Crohn's Disease (UNITI-2) - CNTO1275CRD3003

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severely Active Crohn's Disease (IMUNITI) - CNTO1275CRD3003

PENTASA in active Crohn’s Disease : A 10-week, double-blind, multi-centre trial comparing PENTASA Sachet 6g/day (mesalazine, mesalamine) with placebo (FE999907 CS05)

A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients with Moderate to Severe Crohn’s Disease (C13011)

A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe Ulcerative Colitis (Protocol C13006)

A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn’s Disease (Protocol C13008)

A Multi-center, Investigator-blinded, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Efficacy of 1.6 to 2.4g Asacol Therapy QD Versus Divided Dose (BID) in the Maintenance of Remission of Ulcerative Colitis (2007021)

CURRICULUM
VITAE

RAVI RAVINUTHALA, MD, MRCP, FAASLD

Gastroenterology Trials:

A Multi-center, Investigator-blinded, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Efficacy of 1.6 to 2.4g Asacol Therapy QD Versus Divided Dose (BID) in the Maintenance of Remission of Ulcerative Colitis (2007021)

A Phase 4, Randomized, Active Comparator, Open Label, Multicenter Study To Assess The Safety And Efficacy Of Osmoprep® Tablets Versus Halflytely® And Bisacodyl Tablet Bowel Prep Kit For Colon Cleansing (Protocol Number: OSBP4011)

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet (ALV003-1221)

A Phase IIb Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-936557 in Subjects with Active Ulcerative Colitis (UC) – IM129005

A Phase IIb, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-936557 in Subjects With Active Crohn's Disease (CD) – IM129-008

A Safety, Tolerance and Efficacy Evaluation of 3 Different Bowel Cleansing Treatments in Adult Subjects, Including the Elderly and Subjects with Hepatic or Renal Insufficiency – BLI800-440

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn's Disease Who have Failed or are Intolerant to TNF Antagonist Therapy (Uniti-1) – CNTO1275CRD3001

A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO201 Trichuris Suis Ova Suspenion (TSO) as Compared to Placebo, Followed by a 12 Week Open-Label Treatment Period in Patients with Moderately to Severely Active Crohn's Disease - CNDO201-003

A Randomized, Double-Blind, Active-Controlled Study of CB-183,315 in Patients with Clostridium Difficile Associated Diarrhea (LCD-CDAD-11-06)

A Phase II Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of rhuMAb BETA7 in Patients With Moderate to Severe Ulcerative Colitis (ABS4986g)

A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of rhuMAb BETA7 in Patients With Moderate to Severe Ulcerative Colitis (GA27927)

RAVI RAVINUTHALA, MD, MRCP, FAASLD

Gastroenterology Trials:

A Phase I Double-Blind, Randomized, Placebo-Controlled, Staggered, Single and Multiple Ascending Dose, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 in Subjects with Moderate to Severe Ulcerative Colitis (GS-US-326-0101)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Linaclotide (72ug or 145 ug) Administered Orally for 12 Weeks in Patients with Chronic Idiopathic Constipation (MCP-103-309)

A Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer® vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia (IDA) in an Infusion Center Setting (1VIT13032)

A Multi-Center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia (1VIT08019)

A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe Crohn's Disease (C13007)

Reliance: Research Study to Evaluate LOTRONEX® in Severe IBS-D: Analysis of Current Clinical Practice Environment (10LOT01)

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-Dose Combination RHB-104 in Subjects with Moderately to Severely Active Crohn's Disease (RHB-104-01)

A Double-Blind, Placebo-Controlled, Parallel-Group, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects with Active Moderate Crohn's Disease (RECD3126)

A Phase III, Randomized, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo Over 104 Weeks in the Prevention of Recurrence of Diverticulitis (SPD476-314)

RAVI RAVINUTHALA, MD, MRCP, FAASLD

Gastroenterology Trials:

Numerous Phase I – IV Clinical Trials with Consultants for Clinical Research investigating therapeutic modalities in the treatment of Inflammatory Bowel Disease (Crohn's & Ulcerative Colitis), Irritable Bowel Syndrome, Colon Preparations, Anal Fissures, Iron Deficiency Anemia, Hepatitis, NASH, Gastroparesis, Clostridium Difficile Toxin to name a few.

Pharmaceutical companies sponsoring these studies include: Abbott/Abbvie, Schering, Centocor/J&J/Janssen, Amgen, Biogen, Biolex, Bristol Myer Squibb, Boehringer Ingelheim, Braintree, Coronado, Exact Sciences, Furiex, Forest/Ironwood, Genentech, Luitpoid, Menarini, Mochida, Millennium, Prometheus, Receptos, Redhill, Salix, Sanofi, Shire, Telsar, Tibotec, Tsumara, UCB, Vertex, TAP, Abbott, Merck, Glaxo, Novartis, Solvay, Axcan,, Intermune, Janssen, Proctor & Gamble, Roche, Cubist, and Celltech.

Further Information Available upon request